Statins, the widely used class of drugs for cholesterol management, are now showing promising results in slowing smoking-induced lung damage. In a new study presented at CHEST 2006, the 72nd annual international scientific assembly of the American College of Chest Physicians (ACCP), current and former smokers who used statins had lower lung function decline than those not using statins, regardless of whether patients continued or stopped smoking.
"Until now, no medication has shown to slow smoking-induced lung damage," said Walid G. Younis, MD, University of Oklahoma Medical Center, Oklahoma City, OK. "Our study is the first to show that statins may decrease the decline in lung function in smokers and former smokers, and, therefore, prevent millions from developing debilitating diseases that could eventually lead to death."
Younis and colleagues from the University of Oklahoma Medical Center compared the effects of statins on the management of 182 current smokers and 303 former smokers, with a mean age 66.1 ± 2.1 years, seen at the Oklahoma City Veterans Hospital. Patients had at least two pulmonary function tests, with the time between the first and the last test being 2.7 ± 1.6 years. Patients were categorized by initial level of lung impairment, with 319 having obstructive lung disease, 99 having restrictive lung disease, and 67 patients having normal lung function. Of the patients, 238 were on statin for an average of 2.7 ± 1.8 years, while the remaining patients did not receive statins (control group).
Over the study follow-up period, the decline in FEV1 was 12.8 percent in the control group and 2.5 percent in the statin group. The decline in FVC was 10.3 percent in the control and 1.3 percent in the statin group. Both differences were highly significant. This beneficial effect of statin remained significant, irrespective of the type of lung disease and regardless of whether the patient continued or stopped smoking. Furthermore, statin use in patients with obstructive lung disease led to a 35 percent decline in the rate of respiratory-related emergency department visits and hospitalizations.
Researchers note that it is not known whether decreasing the rate of decline in lung function or whether preventing emphysema, an independent risk factor of lung cancer, could translate into a reduction of lung cancer.
"It is conceivable that long-term statin therapy could be used in smokers and former smokers to prevent and slow the progression of lung diseases," said Dr. Younis. "Even though statins may help with lung function, they have no effect on preventing a patient from the major smoking-related killer, which is lung cancer. Therefore, smokers should never lose their incentive to quit smoking."
"Smoking is the number one cause of lung cancer and chronic lung diseases in the world. Although statins may reduce the incidence of lung damage in smokers, patients must still be urged to stop smoking as the best way to maintain and improve their health," said Mark J. Rosen, MD, FCCP, President of the American College of Chest Physicians.
Jennifer Stawarz | EurekAlert!
Surgery involving ultrasound energy found to treat high blood pressure
24.05.2018 | Queen Mary University of London
XXL computed tomography: a new dimension in X-ray analysis
17.05.2018 | Fraunhofer-Gesellschaft
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences